RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwire - May 14, 2008) - Adherex Technologies Inc. (TSX: AHX)(AMEX: ADH), a biopharmaceutical company devoted to solving problems for patients with cancer, announced today a license agreement with the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI-AVL) for the exclusive use of data from a Phase III trial conducted by Dr. Charlotte Zuur and colleagues of the NKI-AVL with sodium thiosulfate (STS) to prevent hearing loss in adults with head and neck cancer, published in the Journal of Clinical Oncology in August 2007 and entitled "Ototoxicity in a Randomized Phase III Trial of Intra-Arterial Compared With Intravenous Cisplatin Chemoradiation in Patients with Locally Advanced Head and Neck Cancer". The agreement includes an exclusive license to data from a planned study intended to provide long-term follow-up on the hearing status, disease-free status and overall survival of patients from the completed Phase III trial.
